Premium
Cough in Pediatric Patients Receiving Angiotensin‐Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials
Author(s) -
BakerSmith C M,
Benjamin D K,
Califf R M,
Murphy M D,
Li J S,
Smith P B
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.231
Subject(s) - medicine , angiotensin receptor blockers , angiotensin receptor , incidence (geometry) , angiotensin converting enzyme , randomized controlled trial , clinical pharmacology , clinical trial , renin–angiotensin system , pharmacology , angiotensin ii , receptor , blood pressure , physics , optics
The incidence of cough in children receiving antihypertension therapy with angiotensin‐converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) is unknown. We analyzed patient‐level data from eight randomized trials for the treatment of pediatric hypertension, six of them involving ACEis and two involving ARBs. The incidence of cough in children receiving ACEis (reported cough, 3.2%) was similar to that in children receiving ARBs (reported cough, 1.8%) ( P = 0.34). Reports of cough were lower in children than in adults. Clinical Pharmacology & Therapeutics (2010) 87 6, 668–671. doi: 10.1038/clpt.2009.231